Beta Drugs FY26: Margin improvement, a tender-led export reset, and a bigger bet on branded and IVF

Beta Drugs Limited closed FY26 with a year that was stronger on margins than on growth. Management said net revenue increased from 368 crore to 396 crore. Gross margin improved to 55.52% from 52.71%, and EBITDA rose to 86.85 crore from 76.97 crore. EBITDA margin expanded to 22.57% from 21.1%.

PAT, however, did not track EBITDA improvement. Management said net profit margin declined from 11.71% to 10.78% due to extraordinary expenses. They added that, excluding those extraordinary items, the net profit margin would have been above 12.5%. The concall also clarified that FY26 included 9.36 crore of interest booked on compulsory convertible debentures, which management expects to largely disappear after conversion in May 2026.

The FY26 revenue mix, as presented, shows a business still anchored in oncology but increasingly leaning toward higher value segments. Branded formulation revenue was reported at 140 crore, CDMO at 149 crore, exports at 71 crore, and others at 25 crore. This maps to the company’s FY26 market mix split of branded 36%, exports 18%, CDMO 39%, and others 7%.

Segment performance: branded execution offsets a mixed year in exports and CDMO

In branded oncology, management said sales increased from 103 crore to 123 crore, up 20% year on year. The investor deck positions branded oncology as the long-term core, highlighting 135 plus oncology products and availability in more than 85% of corporate and government hospitals. It also notes that the number of brands above 5 crore reached seven in FY26, versus none in FY21.

CDMO was flat in FY26. Management said CDMO moved from 148 crore to 149 crore, and attributed the muted outcome to the absence of Platin supplies in the second half of the year. In their words, CDMO sales would otherwise have been higher by about 7%. Even with a steady-state approach to CDMO, the company’s Vision 2030 presentation clearly points to a deliberate mix shift away from CDMO over time.

Exports were the biggest operational swing factor in FY26. Export revenue declined by 11%, from 79 crore to 71 crore. Management blamed delayed public sector tenders, saying tenders that should have been awarded earlier were only awarded in March 2026. They quantified the impact of missed tenders at about 20 crore to 25 crore. The company expects supply to begin in Q1 FY27 and has guided for more than 50% export growth in FY27. On the concall, management explicitly indicated a target range of 105 crore to 110 crore for FY27 exports.

API sales were another bright spot. Management said API sales grew by 24% to 24.8 crore in FY26. The deck claims 80% of API for formulations is manufactured in-house and positions backward integration as a margin lever. The company highlighted investment of more than 20 crore in FY26 toward backward integration and described this as a cushion against supply chain vulnerabilities.

Dermatology and cosmetology remains smaller in scale but showed momentum. Management said Derma revenue grew from 12.3 crore to 16.58 crore, up about 35%, and stated the business became EBITDA positive over the last six months, with monthly breakeven achieved in FY26. The company also referenced exclusive arrangements to bring European cosmetology products to India and approvals to market mesotherapy.

Vision 2030: mix shift as the main strategy lever

The company’s investor deck outlines a clear transformation arc. From FY21 to FY26, it shows branded contribution rising from 28% to 36%, and CDMO falling from 50% to 39%. The FY30 target takes this much further: branded at 51% and exports at 30%, while CDMO reduces to 13%.

The strategic priorities are framed around six pillars: building a branded oncology franchise, investing in R&D and new product development, ramping exports across regulated and semi-regulated markets through filings, leveraging distribution for Nivian, expanding margins through efficiency and backward integration, and maintaining a strong balance sheet with efficient cash conversion.

Management commentary supports this direction. They said branded oncology can grow 20% to 25% annually over the next three to four years, driven by new launches and deeper penetration. The deck highlights NDDS development and first-to-launch opportunities, with FY26 launches including ADAXATE-OS, CRIZENTA and CAXFILA-OS. The pipeline is also quantified in the deck: 10 products in FY27, 7 each in FY28 and FY29.

Exports are positioned as the second major engine. Core geographies listed are LATAM, Africa, APAC and MENA. On the concall, management said the company submitted more than 200 dossiers over the last one and a half years, expects close to 100 registrations in the year, and has filed three dossiers in the EU with an audit scheduled in September. They also said export EBITDA margins are currently about 20% to 21% and could improve to 23% to 25% as the company enters regulated markets.

Nivian acquisition: IVF adds a parallel branded growth vector

The most material strategic move in FY26 was the acquisition of 66.1% stake in Nivian Lifesciences, with a total consideration of 69.4 crore at a valuation of 105 crore. Management said the transaction closed in April 2026 and that FY27 will include a full-year consolidation.

On the concall, the CFO stated Nivian closed FY26 at 45 crore to 46 crore revenue, with EBITDA margin around 18% to 19% and PAT margin around 9% to 10%. Management expects Nivian to grow at about 30% over the next three to four years. They also described two primary synergy levers: procurement, since Nivian currently procures products externally, and channel expansion into corporate hospitals where Beta has long-standing access.

In the investor deck, Beta estimates the India IVF market at 2,000 crore in FY26 growing to 3,800 crore by FY30, with about 17% CAGR. Nivian is described as having 31 products, a presence across 15 states and UTs, and a 61-member sales team.

Balance sheet and capital allocation signals

The balance sheet summary shows FY26 borrowings at 147.80 crore, up sharply versus FY24, while cash and cash equivalents were 124.84 crore. Debt to equity improved slightly from 0.74 in FY25 to 0.63 in FY26.

Management said FY26 capex was about 45 crore across plants, including land that they later decided to dispose because they shifted to a nearby building for office needs. For the next two years, they do not see major capex, apart from ongoing work on an intermediate plant. The intermediate plant cost was stated at about 27 crore, and management suggested it could lift margins by about 1 to 1.5 percentage points depending on yields, while reducing dependence on China for key starting material documentation.

Closing view

FY26 reinforced Beta Drugs’ thesis that mix, not just topline, is a key determinant of profitability. Branded oncology and API performed well, Derma moved toward profitability, while CDMO and exports were held back by Platin disruptions and tender timing.

FY27 becomes the test year. Management has guided for at least 50% export growth and reiterated a broader ambition of reaching 850 crore to 900 crore revenue over the next four years under Vision 2030. Execution on tender deliveries, new launches, and a smooth Nivian consolidation will determine whether this transformation shifts from roadmap to reality.